Skip to content
    Clinical Trials

    PET-Guided De-Escalation Shows 89.5% 5-Year iDFS in HER2-Positive Breast Cancer

    Pérez-García et alNature medicine

    In the randomized, non-comparative phase 2 PHERGain trial (NCT03161353), investigators evaluated a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with stages I–IIIA operable HER2-positive breast cancer and tumor size ≥ 1.5 cm were randomized to receive chemotherapy plus trastuzumab and pertuzumab (HP; group A) or HP with or without endocrine therapy (group B). In group B, treatment was adapted based on 18F-FDG-PET response after two cycles and subsequent pCR, with chemotherapy administered only to nonresponders or patients without pCR.
    Following a previously reported 3-year invasive disease-free survival (iDFS) of 94.3% (95% CI: 90.9 to 96.8) in group B, the prespecified secondary endpoint analysis at a median follow-up of 5.6 years reported a 5-year iDFS of 89.5% (95% CI: 85.7 to 93.4) in group B (n = 267). Among 18F-FDG-PET responders who achieved pCR without receiving chemotherapy (n = 86), 5-year iDFS was 92.4% (95% CI: 86.7 to 98.5), with one distant recurrence noted; authors note this post-randomization subgroup finding is descriptive rather than a measure of causal effects of chemotherapy omission. Exploratory circulating tumor DNA (ctDNA) analyses revealed that detectable ctDNA at baseline or during therapy was associated with inferior iDFS, whereas ctDNA clearance correlated with higher pCR rates and improved long-term survival outcomes.

    Key Takeaways

    • At a median follow-up of 5.6 years, the 5-year invasive disease-free survival was 89.5% (95% CI: 85.7 to 93.4) in group B (n = 267) and 92.4% (95% CI: 86.7 to 98.5) among 18F-FDG-PET responders who achieved pathological complete response without chemotherapy (n = 86), with one distant recurrence observed.
    • Detectable circulating tumor DNA at baseline or during treatment was associated with inferior invasive disease-free survival, whereas circulating tumor DNA clearance correlated with higher pathological complete response rates and improved long-term outcomes.